STAT+:mRNA 癌症疫苗试验结果喜忧参半,行业直面关键难题
STAT+: Divergent trial results on cancer vaccines have the field grappling with hard questions
Merck 和 Moderna 8 月报告,mRNA 癌症疫苗 intismeran autogene 联合现有治疗延缓了黑色素瘤复发与扩散。这一晚期试验结果增强了利用 mRNA 训练免疫系统攻击癌细胞应用于其他癌症的希望,但针对哪些癌症及 mRNA 是否具备相应能力仍属未知。
The approach, and the use of mRNA, is still exciting researchers, though much remains unknown
![]()
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.
The recent success of a late-stage mRNA cancer vaccine, showing the drug stopped the return of melanoma, has boosted hopes that the approach can be successfully harnessed to attack other cancers.
The question now is which ones — and whether mRNA is up to the task.
Merck and Moderna reported in August that adding their mRNA cancer vaccine to an existing treatment slowed the return and spread of melanoma. The field had been waiting “with bated breath” for the news on the drug, called intismeran autogene, said Karen Knudsen, the CEO of the Parker Institute for Cancer Immunotherapy, the research organization founded by tech entrepreneur Sean Parker. The results suggested that the idea of using messenger RNA to train the immune system to attack cancer cells — an approach first devised decades ago — was ripe for further drug development.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
Biotech Startups and Venture Capital Reporter
Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01.
来源:STAT 主站 · statnews.com